TG Therapeutics Inc. (NASDAQ: TGTX) announced the presentation of data on BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis at the American Academy of Neurology 2026 annual meeting in Chicago.

The company will present two poster presentations featuring results from the ENABLE and ENHANCE studies. The ENABLE study represents the first Phase 4 observational study for patients with relapsing multiple sclerosis initiating ublituximab, focusing on real-world clinical experience. The ENHANCE study examines safety and tolerability of a modified ublituximab dosing regimen.

BRIUMVI is approved by the FDA for treating adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug is a monoclonal antibody that targets CD20-expressing B-cells and utilizes glycoengineering to enable efficient B-cell depletion at low doses.

The presentations will be led by Dr. Carrie Hersh from Cleveland Clinic Lou Ruvo Center for Brain Health and Dr. Barry A. Singer from The MS Center for Innovations in Care at Missouri Baptist Medical Center.

Multiple sclerosis affects nearly 1 million people in the United States, with approximately 85% initially diagnosed with relapsing-remitting multiple sclerosis. Worldwide, more than 2.3 million people have a diagnosis of MS.

TG Therapeutics is a commercial-stage biotechnology company focused on treatments for B-cell diseases, based on information from a company press release.